AARD

Aardvark Therapeutics Inc

1.33

Nov 13 • 3:59 PM ET -0.19 (-12.50%)

1.35

Aftermarket • 7:28 PM ET +0.02 (1.64%)

Healthcare Biotechnology USA Nano NASD

Nov 13, 10:45 AMAardvark Therapeutics Inc reports fiscal Q3 2026 results with non-GAAP EPS $-0.88 (-17% YoY) and revenue $0, misses EPS but beats revenue estimates

Peers: RYTM HRMY ACAD CRBP PTN ALT GPCR SKYE VKTX AMLX

| Held by: VTI VXF IBB IWC BUSM DXUV IBBQ DFMC BIB

Scroll to Statements

Index	-
Market Cap	29.11M
Enterprise Value	-30.67M
Income	-72.76M
Sales	0.00M
Book/sh	2.63
Cash/sh	2.76
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	40
IPO	Feb 13, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.51
P/C	0.48
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	9.11
Current Ratio	9.11
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-3.33
EPS next Y	-2.37
EPS next Q	-0.74
EPS this Y	-10.98%
EPS next Y	27.26%
EPS next 5Y	8.57%
EPS past 3/5Y	-60.85% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-48.29%
Sales Y/Y TTM	-
EPS Q/Q	-16.83%
Sales Q/Q	-
Earnings	Nov 13 BMO
EPS/Sales Surpr.	-21.46% -

Insider Own	41.42%
Insider Trans	-0.84%
Inst Own	25.26%
Inst Trans	-5.27%
ROA	-73.48%
ROE	-80.85%
ROIC	-125.95%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-28.51%
SMA50	-64.62%
SMA200	-76.44%
Trades

Shs Outstand	21.89M
Shs Float	12.82M
Short Float	8.10%
Short Ratio	1.69
Short Interest	1.04M
52W High	16.60 -91.99%
52W Low	0.93 43.01%
Volatility	19.01% 21.66%
ATR (14)	0.36
RSI (14)	31.62
Beta	4.30
Rel Volume	0.66
Avg Volume	614.02K
Volume	403,074

Perf Week	13.68%
Perf Month	-65.54%
Perf Quarter	-80.27%
Perf Half Y	-70.90%
Perf YTD	-89.87%
Perf Year	-87.75%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	2.55
Target Price	4.57
Prev Close	1.52
Price	1.33
Change %	-12.50%

Consensus

Hold

Avg. Price Target

$4.57

Implied Upside

+243.6%

Analysts11incl. previous ratings

Rating Distribution6 Buy · 4 Hold · 1 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 05, 2026	Downgrade	RRaymond James	Strong Buy → Mkt Perform
May 15, 2026	Downgrade	MMorgan Stanley	Equal-Weight → Underweight	$3	+125.6%
Mar 02, 2026	Downgrade	SStifel	Buy → Hold	$6	+351.1%
Mar 02, 2026	Downgrade	RRBC Capital Mkts	Outperform → Sector Perform	$6	+351.1%
Mar 02, 2026	Downgrade	MMorgan Stanley	Overweight → Equal-Weight	$7	+426.3%
Mar 02, 2026	Downgrade	HH.C. Wainwright	Buy → Neutral
Jan 28, 2026	Initiated	RB. Riley Securities	Buy	$32	+2,306.0%
Dec 23, 2025	Initiated	OOppenheimer	Outperform	$35	+2,531.6%
Dec 12, 2025	Initiated	WWilliam Blair	Outperform
Dec 03, 2025	Initiated	RRaymond James	Strong Buy	$47	+3,433.8%
Nov 07, 2025	Initiated	BBTIG Research	Buy	$26	+1,854.9%
Sep 29, 2025	Initiated	SStifel	Buy	$24	+1,704.5%
Jun 30, 2025	Initiated	HH.C. Wainwright	Buy	$40	+2,907.5%
Mar 10, 2025	Initiated	RRBC Capital Mkts	Outperform	$21	+1,478.9%
Mar 10, 2025	Initiated	MMorgan Stanley	Overweight	$29	+2,080.5%
Mar 10, 2025	Initiated	CCantor Fitzgerald	Overweight	$50	+3,659.4%
Mar 10, 2025	Initiated	BBofA Securities	Buy	$22	+1,554.1%

Nov-13-26 08:00AM	Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -12.50%
Oct-23-26 07:00AM	Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials (GlobeNewswire) -64.81%
Oct-22-26 05:57PM	Aardvark Therapeutics stock surges as FDA lifts clinical hold (Investing.com) -10.43%
04:05PM	Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data (GlobeNewswire)
Oct-12-26 02:29AM	Aardvark Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - AARD (PR Newswire) -6.51%
08:00AM	Loading…
Oct-08-26 08:00AM	Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors (GlobeNewswire) -5.04%
Oct-05-26 12:15PM	If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses (Newsfile)
Oct-02-26 04:05PM	Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.31%
Sep-17-26 03:25PM	Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101 (Newsfile) +7.38%
Sep-04-26 05:21PM	AARD Stockholders Have Rights - If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses (Business Wire) -6.11%
Aug-25-26 09:02AM	Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately (PR Newswire) +5.38%
Aug-24-26 01:01PM	Did You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARD (Newsfile)
Aug-17-26 01:31PM	Aardvark Therapeutics Inc (AARD) (Q2 2026) Earnings Call Highlights: Board Re-Elected, Auditor ... (GuruFocus.com)
Aug-11-26 04:53PM	Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) -8.62%
Jul-22-26 04:00PM	Aardvark Therapeutics (AARD) Scrutinized Again After FDA Hold on Lead Drug Candidate, May Announcement Drives Stock 32% Lower - Hagens Berman (PR Newswire) +6.58%
09:00AM	Loading…
Jun-25-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire)
Jun-19-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire)
May-21-26 09:00AM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS (PR Newswire) +5.13%
May-15-26 07:58AM	FDA hold puts Aardvark Prader-Willi drug in limbo (BioPharma Dive) -32.10%
May-14-26 04:01PM	Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold (GlobeNewswire)
May-07-26 08:00AM	Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-10-26 04:17PM	Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman (PR Newswire)
Mar-23-26 04:05PM	Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire) -7.26%
Mar-04-26 08:54AM	What's Going On With Aardvark Therapeutics Stock On Wednesday? (Benzinga) +15.10%
Mar-02-26 09:49AM	Why Aardvark Therapeutics Just Lost More Than Half Its Value (Investor's Business Daily) -56.20%
07:02AM	Why Is Aardvark Therapeutics Stock Sinking Monday? (Benzinga)
05:23AM	Stock Market Today: S&P 500, Dow Jones Futures Slide Amid War Against Iran- AMTD Digital, Aardvark, MongoDB In Focus (Benzinga)
03:26AM	Safety concerns spur Aardvark to halt key Prader-Willi drug trial (BioPharma Dive)
Feb-27-26 04:05PM	Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome (GlobeNewswire)
Feb-13-26 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Feb-12-26 08:00AM	Aardvark Therapeutics Announces Leadership Appointments (GlobeNewswire)
08:00AM	Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer (GlobeNewswire)
Feb-10-26 08:00AM	Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome (GlobeNewswire) -6.45%
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
Dec-11-25 04:27PM	Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win (Investor's Business Daily) +11.66% -7.56%
Dec-10-25 04:05PM	Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome (GlobeNewswire)
Nov-25-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in December (GlobeNewswire)
Nov-13-25 04:05PM	Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) -8.66%
Nov-11-25 04:05PM	Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.94%
Nov-07-25 09:33AM	Datadog, Trade Desk upgraded: Wall Street's top analyst calls (The Fly)
Nov-04-25 12:00PM	Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 (GlobeNewswire) -5.68%
Nov-03-25 05:55PM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
08:00AM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-22-25 08:00AM	Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek (GlobeNewswire) -8.28%
Oct-17-25 09:27AM	Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment (Insider Monkey)
Oct-08-25 08:00AM	Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome (GlobeNewswire)
Sep-23-25 04:05PM	Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum (GlobeNewswire) +6.38%
Sep-22-25 08:01AM	MapLight lines up an IPO in bid to challenge Bristol Myers schizophrenia drug (BioPharma Dive)
Sep-10-25 09:22PM	LB Pharmaceuticals raises $285 million in US IPO (Reuters)
Sep-04-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-27-25 04:10PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in September (GlobeNewswire) -5.67% -5.56%
Aug-13-25 04:10PM	Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates (GlobeNewswire) +11.55%
Aug-12-25 08:00AM	Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy (GlobeNewswire) -9.96%
Jul-18-25 08:00AM	Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-15-25 07:30AM	OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company (PR Newswire)
Jul-01-25 05:31PM	Aardvark's Hunger-Suppressing Drug Promises Weight Loss Without GI Distress (Benzinga)
Jun-24-25 08:00AM	Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference (GlobeNewswire) +18.23%
Jun-03-25 09:55AM	Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet (Zacks)
May-19-25 04:10PM	Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions (GlobeNewswire) +5.46% +5.47%
May-14-25 04:10PM	Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) -13.81%
May-07-25 04:05PM	Aardvark Therapeutics to Present at Upcoming Investor Conferences in May (GlobeNewswire)
Mar-31-25 04:10PM	Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +10.39%
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) -5.52% -13.03%
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha) +7.95%
Mar-14-25 11:25AM	Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-03-25 02:55PM	Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-12-25 10:38PM	Aardvark Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sun Nelson	See Remarks	Sep 11 '26	Sale	5.18	62,000	321,179	35,475	Sep 11 08:14 PM
Sun Nelson	See Remarks	Sep 10 '26	Sale	5.00	14,754	73,779	97,475	Sep 11 08:14 PM
NELSON SUN	Officer	Sep 11 '26	Proposed Sale	5.01	33,911	169,894		Sep 11 04:51 PM
NELSON SUN	Officer	Sep 10 '26	Proposed Sale	4.92	42,843	210,788		Sep 10 05:18 PM
Sun Nelson	Chief Financial Officer	Dec 11 '25	Buy	14.40	3,000	43,200	108,484	Dec 12 08:30 PM
Lee Tien-Li	Chief Executive Officer	Dec 11 '25	Buy	14.48	7,000	101,395	1,551,613	Dec 12 08:30 PM

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

CEODr. Tien-Li Lee M.D.

CFO & COOMr. Nelson B. Sun M.B.A.

M.P.H.Dr. Manasi Sinha Jaiman M.D.

Executive Vice President of Medical AffairsDr. Dvorit Samid Ph.D.

Chief Research OfficerDr. Zhenhuan Zheng Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

AARD

Aardvark Therapeutics Inc

Upgrade your Finviz experience

All the Features.
Half the Price.